Table 9.

Ongoing clinical trials assessing the efficacy of RANK inhibitors in lung cancer.

Inhibitor	NCT number	Phase	Population	Treatment	Estimated enrollment	Primary outcome	Status
Denosumab	NCT03669523	II	NSCLC with bone metastasis	Denosumab+nivolumab	86	ORR	Recruiting
	NCT03958565	NA	Pathologically confirmed NSCLC with bone metastasis but no driver oncogene	Denosumab 120 mg	100	Percentage reduction of urine NTx and serum CTx	Recruiting

NSCLC, non-small cell lung cancer; RANK, receptor activator of nuclear factor kB; ORR, objective response rate.NA, missing value.